Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept for Acute Graft-Versus-Host Disease
NCT00141713Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Oct 2003
- Primary completion
- Nov 2006
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etanercept in Acute Graft-Versus-Host Disease (aGvHD), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Response Rate of Etanercept with Steroids at 3 months. Started Oct 2003; status: completed.
02
Drugs
etanercept
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT00141713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00141713.